Events focused on eliminating specific proteins within cells, typically through small-molecule induced proximity, represent a burgeoning area of research in drug discovery and development. These meetings bring together experts from diverse fields such as chemistry, biology, pharmacology, and clinical medicine. A typical gathering might involve presentations on novel degrader molecules, discussions of emerging therapeutic targets, and analyses of clinical trial results. For example, sessions could cover PROTACs (proteolysis-targeting chimeras), molecular glues, or other degradation technologies.
Such assemblies are crucial for advancing this rapidly evolving field. They foster collaboration and information exchange among researchers, accelerating the development of new therapies for a range of diseases, including cancer, neurodegenerative disorders, and infectious diseases. Historically, drug development has focused on inhibiting protein function. However, this approach is limited by the “druggability” of target proteins. Eliminating disease-causing proteins entirely offers a novel and potentially more effective therapeutic strategy.
